Trial Profile
Randomized, Double-Blind Prospective Clinical Study to Examine the Mechanism of Action of IG-RD-001 (Ze-339) Compared to Desloratadine and Placebo in Patients With Seasonal Allergic Rhinitis Who Are Sensitized to Grasses.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2012
Price :
$35
*
At a glance
- Drugs IG RD 001 (Primary) ; Desloratadine
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Acronyms PETRA
- 04 May 2011 New trial record
- 11 Apr 2011 Results published in the Journal of Allergy and Clinical Immunology.
- 11 Apr 2011 Primary endpoint "Time-to-resolution-of-nasal-symptoms" has been met, based on results published in The Journal of Allergy and Clinical Immunology.